Physician

Internal Medicine

Scott A. Waldman, MD practices Internal Medicine. He went to medical school at Stanford University School of Medicine. Stanford University School of Medicine is a top medical university. Stanford University School of Medicine has a rank of 2 in research and a 25 in primary care Doctor Scott A. Waldman, MD is a published doctor and has 97 publications published. The lastest was: 'Big Data Transforms Discovery-Utilization Therapeutics Continuum.'

Publications

---

• Big Data Transforms Discovery-Utilization Therapeutics Continuum.
• Clinical Pharmacology & Therapeutics: the next five years.
• Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease.
• The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer.
• GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
• Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
• Tumor Radiation Therapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C.
• Managing the innovation supply chain to maximize personalized medicine.
• Antiobesity Pharmacotherapy: New Drugs and Emerging Targets.
• Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
• New advances in models and strategies for developing anti-obesity drugs.
• Systems-based discovery advances drug development.
• Molecular staging of node negative patients with colorectal cancer.
• Advances in cancer immunotherapy.
• Guanylyl cyclase C as a biomarker in colorectal cancer.
• Immunotherapeutic strategies to target prognostic and predictive markers of cancer.
• Translational medicine individualizes healthcare discovery, development and delivery.
• Obesity pharmacotherapy: What is next?
• Molecular insights provide the critical path to disease mitigation.
• GUCY2C: at the intersection of obesity and cancer.
• The adipose tissue production of adiponectin is increased in end-stage renal disease.
• Advancing pharmacometrics and systems pharmacology.
• Molecular staging individualizing cancer management.
• Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.
• Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
• GUCY2C-targeted cancer immunotherapy: past, present and future.
• Widening the path to personalized medicine.
• A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.
• Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.
• Phosphorylation of vasodilator-stimulated phosphoprotein ser239 suppresses filopodia and invadopodia in colon cancer.
• Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.
• Contrast-enhanced ultrasound imaging of sentinel lymph nodes after peritumoral administration of Sonazoid in a melanoma tumor animal model.
• Bionic technologies transforming the science of healthcare delivery.
• Regulation of appetite to treat obesity.
• Clinical translational science 2020: disruptive innovation redefines the discovery-application enterprise.
• A Conserved Tissue-Specific Homeodomain-Less Isoform of MEIS1 Is Downregulated in Colorectal Cancer.
• Clinical and translational science: from bench-bedside to global village.
• Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.
• Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
• Molecular therapy drives patient-centric health care paradigms.
• Sizing up pharmacotherapy for obesity.
• Taking a lesson from microbial diarrheagenesis in the management of chronic constipation.
• The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
• Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
• Molecular staging estimates occult tumor burden in colorectal cancer.
• Experimental therapeutics: a paradigm for personalized medicine.
• Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis.
• Applications of microRNA in cancer: Exploring the advantages of miRNA.
• Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9.
• Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
• Translational medicine in the era of health care reform.
• Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
• Molecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy.
• Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.
• The roadmap to personalized medicine.
• Sex modulates intestinal transformation by the tumor-suppressor GCC.
• Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
• MicroRNA signatures as diagnostic and therapeutic targets.
• Clinical and translational sciences: at the intersection of molecular and individualized medicine.
• Derivation and fluidity of acutely induced dysfunctional CD8+ T cells.
• STa peptide analogs for probing guanylyl cyclase C.
• Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine.
• Acquired and innate cardioprotection.
• Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.
• The pharmacokinetics of taurolidine metabolites in healthy volunteers.
• Translating MicroRNA discovery into clinical biomarkers in cancer.
• H-ras inhibits RhoA/ROCK leading to a decrease in the basal tone in the internal anal sphincter.
• A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal ca...
• Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells.
• Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells.
• Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.
• Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
• The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas.
• Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins.
• Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
• Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
• Potential for interactions between caspofungin and nelfinavir or rifampin.
• Markers of cell cycle-mediated drug resistance and prognosis of patients receiving preoperative combined modality therapy for rectal cancer.
• The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.
• Indinavir and rifabutin drug interactions in healthy volunteers.
• Nitric oxide signaling: systems integration of oxygen balance in defense of cell integrity.
• The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers.
• Reciprocal regulation and integration of signaling by intracellular calcium and cyclic GMP.
• Effect of mibefradil on CYP3A4 in vivo.
• Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation.
• Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
• Functional and molecular characterization of beta-adrenoceptors in the internal anal sphincter.
• Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
• Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.
• Does potency predict clinical efficacy? Illustration through an antihistamine model.
• A comparative molecular field analysis (COMFA) of the structural determinants of heat-stable enterotoxins mediating activation of guanylyl cyclase C.
• Nitric oxide activation of soluble guanylyl cyclase reveals high and low affinity sites that mediate allosteric inhibition by calcium.
• Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
• In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
• Companion diagnostics at the intersection of personalized medicine and healthcare delivery.
• Systems approaches evolve clinical pharmacology.

Schools

---

• Stanford University

• Stanford

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

Education

---

• Stanford University
• Stanford University School of Medicine

Hospital

---

• Thomas Jefferson University Hospital

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Gloria L. Finley, NP
	Dr. Apeksha Shah, MD This Doctor is OpenDoctor Recommended.
	Dr. Sunaina K. Kaushal, MD This Doctor is OpenDoctor Recommended.
	Dr. Mary N. Halak, MD This Doctor is OpenDoctor Recommended.
	Dr. Abigail D. Khan, MD This Doctor is OpenDoctor Recommended.
	Dr. Christina J. Tofani, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniel J. Leonard Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Joanne M. Ilustre, DO
	Dr. Luis A. Taboada, MD This Doctor is OpenDoctor Recommended.
	Dr. Rebecca C. Jaffe, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog